| Autor: |
Singh R; Department of Comparative Biosciences and the Carle Illinois College of Medicine and the Cancer Center of Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Fazal Z; Department of Comparative Biosciences and the Carle Illinois College of Medicine and the Cancer Center of Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Freemantle SJ; Department of Comparative Biosciences and the Carle Illinois College of Medicine and the Cancer Center of Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Spinella MJ; Department of Comparative Biosciences and the Carle Illinois College of Medicine and the Cancer Center of Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Cancers [Cancers (Basel)] 2021 Mar 25; Vol. 13 (7). Date of Electronic Publication: 2021 Mar 25. |
| DOI: |
10.3390/cancers13071506 |
| Abstrakt: |
Compared to many common solid tumors, the main genetic drivers of most testicular germ cell tumors (TGCTs) are unknown. Decades of focus on genomic alterations in TGCTs including awareness of a near universal increase in copies of chromosome 12p have failed to uncover exceptional driver genes, especially in genes that can be targeted therapeutically. Thus far, TGCT patients have missed out on the benefits of targeted therapies available to treat most other malignancies. In the past decade there has been a greater appreciation that epigenetics may play an especially prominent role in TGCT etiology, progression, and hypersensitivity to conventional chemotherapy. While genetics undoubtedly plays a role in TGCT biology, this mini-review will focus on the epigenetic "states" or features of testicular cancer, with an emphasis on DNA methylation, histone modifications, and miRNAs associated with TGCT susceptibility, initiation, progression, and response to chemotherapy. In addition, we comment on the current status of epigenetic-based therapy and epigenetic biomarker development for TGCTs. Finally, we suggest a unifying "rock and a hard place" or "differentiate or die" model where the tumorigenicity and curability of TGCTs are both dependent on common but still ill-defined epigenetic states. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
